CIPLA

BSE: 500087 04 Nov 2025

Healthcare

₹ 1510.5

Cipla Ltd., specializes in Pharmaceuticals within the Healthcare sector.

CIPLA

BSE: 500087 04 Nov 2025

Healthcare

₹ 1510.5

Cipla Ltd., specializes in Pharmaceuticals within the Healthcare sector.

Book Value

386.0

Dividend Yield

0.87%

Debt to Equity

0.01

Stock P/E

22.5

Market Cap

1,21,115 Cr

CIPLA - Share Price & Details

Market Cap

₹1,21,115

High /Low

1,702 / 1,310

Stock P/E

22.5

Book Value

₹386.0

Dividend Yield

0.87

ROCE

22.7

ROE

₹17.8

Face Value

2.0

PEG Ratio

0.87

EVEBITDA

₹14.8

Debt

438

CMP / FCF

43.2

Debt to equity

₹0.01

NP Ann

5,269

High price all time

1,702

Piotroski score

₹7.0

Graham Number

762.0

No. Eq. Shares

80.8

Net CF

₹30.3

Net profit

5,385

Price to book value

3.88

Interest Coverage

₹121.0

Low price all time

84.7

Industry PE

33.0

Reserves

₹31,032

Free Cash Flow

₹3,490

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
31 Oct 2025	Prabhudas Lilladher	Buy	₹1,540.5	₹1,675	11.5%	moneycontrol	View
31 Oct 2025	Choice Equity Broking	Sell	₹1,540.5	₹1,580	5.2%	moneycontrol	View
08 Sep 2025	Deven Choksey	Hold	₹1,541.4	₹1,570	1.8%	moneycontrol	View
02 Sep 2025	Mirae Asset Sharekhan	Buy	₹1,568.95	₹1,754	11.1%	moneycontrol	View
27 Jul 2025	Prabhudas Lilladher	Buy	₹1,531.1	₹1,730	9.9%	moneycontrol	View
26 Jul 2025	ICICI Securities	Buy	₹1,531.1	₹1,800	14.3%	moneycontrol	View
14 May 2025	Prabhudas Lilladher	Buy	₹1,495.4	₹1,730	15.1%	moneycontrol	View
11 Apr 2025	Prabhudas Lilladher	Buy	₹1,416.3	₹1,730	18.2%	moneycontrol	View
31 Jan 2025	KRChoksey	Buy	₹1,458.15	₹1,598	8%	moneycontrol	View
29 Jan 2025	Prabhudas Lilladher	Buy	₹1,423.95	₹1,730	18.7%	moneycontrol	View
28 Jan 2025	Motilal Oswal	Hold	₹1,419.55	₹1,530	4.9%	moneycontrol	View
17 Jan 2025	Asit C. Mehta	Buy	₹1,442.45	₹1,808	27.2%	moneycontrol	View
04 Dec 2024	Geojit Financial Services	Buy	₹1,501.1	₹1,695	13.1%	moneycontrol	View
28 Nov 2024	Prabhudas Lilladher	Buy	₹1,492.85	₹1,730	12%	moneycontrol	View
04 Nov 2024	KRChoksey	Buy	₹1,584.55	₹1,680	8.8%	moneycontrol	View
30 Oct 2024	Prabhudas Lilladher	Buy	₹1,417.45	₹1,615	4.6%	moneycontrol	View
29 Oct 2024	Sharekhan	Buy	₹1,478.1	₹1,715	11%	moneycontrol	View
02 Aug 2024	KRChoksey	Buy	₹1,528.8	₹1,633	6.4%	moneycontrol	View
28 Jul 2024	Prabhudas Lilladher	Buy	₹1,578.25	₹1,680	9.5%	moneycontrol	View
26 Jul 2024	Motilal Oswal	Buy	₹1,578.25	₹1,830	19.3%	moneycontrol	View
26 Jun 2024	Motilal Oswal	Buy	₹1,479.45	₹1,700	10.8%	moneycontrol	View
16 May 2024	Sharekhan	Buy	₹1,420.05	₹1,600	4.3%	moneycontrol	View
13 May 2024	KRChoksey	Buy	₹1,414.8	₹1,633	6.4%	moneycontrol	View
11 May 2024	Prabhudas Lilladher	Buy	₹1,339.45	₹1,405	-8.4%	moneycontrol	View
10 May 2024	Motilal Oswal	Buy	₹1,339.45	₹1,600	4.3%	moneycontrol	View
14 Mar 2024	Sharekhan	Buy	₹1,497.05	₹1,700	10.8%	moneycontrol	View
29 Jan 2024	KRChoksey	Buy	₹1,337.25	₹1,592	3.7%	moneycontrol	View
26 Jan 2024	ICICI Securities	Buy	₹1,369.8	₹1,660	8.2%	moneycontrol	View
26 Jan 2024	Prabhudas Lilladher	Buy	₹1,369.8	₹1,400	-8.7%	moneycontrol	View
25 Jan 2024	Motilal Oswal	Buy	₹1,369.8	₹1,600	4.3%	moneycontrol	View
16 Jan 2024	Motilal Oswal	Buy	₹1,301.45	₹1,540	0.3%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	2.21	-0.31	NA	-1.25	0
CIPLA LTD.	53172.4	13031.3	50461.7	16.12	1,21,115	22.5
TORRENT PHARMACEUTICALS LTD.	26110.0	5510.0	26160.0	16.28	120515	59.7
Max Healthcare Institute Limit	7738.7	1660.3	6940.2	1.7	109221	91.0

Peer Comparison Chart

About CIPLA

Cipla Ltd.,, with Security Code 500087, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Trump's pharma tariffs: Sun Pharma, Cipla to Dr Reddy's — why experts see a sharp rebound on Monday? EXPLAINED

(27 Sep 2025)

Trump's pharma tariffs: Analysts believe Indian pharma companies, primarily focused on generics, will largely avoid impact due to the...

Cipla, Biocon, Lupin, Other Pharma Stocks Under Pressure Post Trumps 100% Tariff

(26 Sep 2025)

Nifty Pharma index declined 2.67% intraday on Friday after US President Donald Trump announced a 100% tariff on the sector with an exception...

The impact of Trump tariff on Indian Pharma is limited at best | Business News

(26 Sep 2025)

The adverse reaction of pharma stocks—from Sun Pharma to Dr Reddy's and Cipla—to 100% US tariffs on pharma imports is largely unfounded.

Trump’s 100% tariffs on pharma: Sun Pharma, Biocon, Cipla & other pharmaceutical stocks tank; jitters on

(26 Sep 2025)

India Business News: Pharmaceutical stocks, particularly Indian firms, plummeted following President Trump's announcement of 100% tariffs on...

Pharma stocks led by Natco, Wockhardt fall up to 5% after US tariffs on generic, patented drugs

(26 Sep 2025)

Indian Pharma companies, from Sun Pharma Ltd. to Aurobindo Pharma Ltd., Gland Pharma Ltd., Lupin Ltd., Cipla Ltd. among others fell up to 5%...

Cipla, Zydus, Dr Reddy’s, and More Pharma Shares Plunge As Trump Imposes New 100% Tariff; Check Details

(26 Sep 2025)

These early losses reflect investor concerns about the recent tariff announcements impacting the pharmaceutical sector., Markets, Times Now.

Quarterly Table

Standalone Consolidated

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	3,893.7	4,318.2	4,664.7	4,381.3	4,036.7	4,501.1	4,775.0	4,970.9	4,797.9	5,046.2
Expenses	3,094.0	3,113.5	3,285.6	3,025.5	3,208.8	3,141.2	3,337.0	3,309.1	3,479.1	3,421.7
Operating Profit	799.8	1,204.7	1,379.1	1,355.9	827.9	1,359.9	1,438.0	1,661.8	1,318.8	1,624.5
OPM %	20.54%	27.9%	29.56%	30.95%	20.51%	30.21%	30.12%	33.43%	27.49%	32.19%
Other Income	-66.2	158.0	205.1	169.0	538.6	213.5	289.1	188.7	588.0	271.1
Interest	10.5	0.3	7.8	9.1	5.5	5.1	3.0	3.6	3.5	5.9
Depreciation	161.6	136.0	179.8	135.0	136.8	137.9	145.7	142.6	147.7	145.7
Profit before tax	747.5	1,226.4	1,396.6	1,380.8	1,224.2	1,430.5	1,578.5	1,704.4	1,461.0	1,744.0
Tax %	-36.7%	-27%	-26.3%	-26.3%	-19.8%	-26.2%	-25.4%	15.6%	-15.4%	25.3%
Net Profit	355.5	895.0	1,029.7	1,114.1	1,038.4	1,055.9	1,178.2	1,438.2	1,485.4	1,303.1
EPS in Rs	4.4	11.08	12.75	13.79	12.85	13.07	14.58	17.79	0	16.12

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	5,810.1	5,739.3	6,328.9	6,678.2	6,603.8	6,163.2	6,693.9	7,051.0	7,073.0	6,729.7
Expenses	4,402.8	4,567.2	4,835.0	4,944.9	4,856.4	4,849.9	4,978.1	5,166.4	5,093.2	5,202.9
Operating Profit	1,407.3	1,172.1	1,493.9	1,733.3	1,747.4	1,313.3	1,715.8	1,884.6	1,979.8	1,526.8
OPM %	24.22%	20.42%	23.6%	25.95%	26.46%	21.31%	25.63%	26.73%	27.99%	22.69%
Other Income	114.4	-47.8	136.3	176.3	-10.2	249.3	160.2	190.6	221.6	289.5
Interest	31.8	34.4	16.4	25.8	30.1	17.6	18.0	15.4	14.6	14.0
Depreciation	272.1	346.2	239.2	290.0	233.4	288.3	246.7	271.7	279.8	308.7
Profit before tax	1,217.8	926.2	1,374.6	1,593.8	1,668.5	1,256.7	1,611.4	1,788.1	1,907.0	1,493.5
Tax %	-33.7%	-29.8%	-27.5%	-27.5%	-27.5%	-25.8%	27%	-27%	-17.3%	-18.6%
Net Profit	807.8	521.5	998.1	1,155.4	1,068.4	931.9	1,175.5	1,305.0	1,574.6	1,214.1
EPS in Rs	9.92	6.51	12.33	14	13.07	11.62	14.57	16.12	19.43	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	7%
5 Years:	9%
3 Years:	7%
TTM:	15%

Compounded Profit Growth
10 Years:	16%
5 Years:	17%
3 Years:	19%
TTM:	22%

Stock Price CAGR
10 Years:	8%
5 Years:	18%
3 Years:	15%
1 Year:	-1%

Compounded Sales Growth
10 Years:	9%
5 Years:	10%
3 Years:	8%
TTM:	7%

Compounded Profit Growth
10 Years:	16%
5 Years:	30%
3 Years:	27%
TTM:	25%

Stock Price CAGR
10 Years:	8%
5 Years:	18%
3 Years:	15%
1 Year:	-1%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

CIPLA

CIPLA

CIPLA - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About CIPLA

Order Book

Latest News

Trump's pharma tariffs: Sun Pharma, Cipla to Dr Reddy's — why experts see a sharp rebound on Monday? EXPLAINED

Cipla, Biocon, Lupin, Other Pharma Stocks Under Pressure Post Trumps 100% Tariff

The impact of Trump tariff on Indian Pharma is limited at best | Business News

Trump’s 100% tariffs on pharma: Sun Pharma, Biocon, Cipla & other pharmaceutical stocks tank; jitters on

Pharma stocks led by Natco, Wockhardt fall up to 5% after US tariffs on generic, patented drugs

Cipla, Zydus, Dr Reddy’s, and More Pharma Shares Plunge As Trump Imposes New 100% Tariff; Check Details

Sun Pharma, Cipla or Dr Reddy's: Which pharma major is most vulnerable to Trump's 100% tariff

Cipla shares decline 1.37% amid volume surge

Sun Pharma, Cipla, Dr Reddy’s: Which Pharma Giant Faces Maximum Risk From Trump’s 100% Tariff?

Cipla, Dr. Reddy's, Sun Pharma: Why pharma stocks are falling today

Cipla Adjusts Evaluation Amid Mixed Performance and Market Sentiment Changes

Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares

Leadership Shift at Cipla: Umang Vohra to Exit, Achin Gupta Likely to Take Over as Global CEO

Cipla CEO Transition: Umang Vohra to Exit, Achin Gupta Likely Successor

Umang Vohra to reportedly step down as Cipla CEO: All about his education qualifications and career

CDSCO Panel Approves Cipla's Levormeloxifene Study Amendment, Mandates Transvaginal Sonography

Cipla CEO Umang Vohra to exit role at end of current fiscal year

Cipla CEO Umang Vohra set to exit; COO Achin Gupta may take over

Cipla MD Umang Vohra likely to step down; COO Achin Gupta may succeed him: Reports

Who is Achin Gupta? Cipla to get new Global CEO as Umang Vohra will step down

Navratri Stock Picks 2025: Paytm, ICICI Bank, Tata Power, Airtel, Cipla and 4 more

Cipla's Technical Indicators Signal Resilience Amid Market Dynamics and Stock Performance

Teva Drops Cipla Qvar Inhaler Patent Row Amid FTC Delisting Push

Cipla share price falls 1.67% on Monday; stock among top losers on Nifty 50

Cipla Share Price Live Updates: Cipla's beta indicates consistent market behavior

Top Gainers and Losers Today, 15 September 2025: Jio Financial Services Ltd, Bajaj Finance Ltd lead gains; Asian Paints Ltd, Cipla Ltd among top losers

Sun Pharma, Cipla, Dr Reddy’s, Zydus Lifesciences, Divi’s Labs, Torrent Pharma et al: Parsing through the pharma value chain

Sun Pharma and Cipla better placed against tariff risk, says analyst

Hold Cipla; target of Rs 1570: Deven Choksey

Cipla Launches HUENA®, India’s First Non-Antibiotic UTI Drug

Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly

Cipla introduces HUENA® – First non-antibiotic drug for recurring UT infections

Cipla launches Huena, India's first non-antibiotic drug to fight UTI

Cipla Launches Non-Antibiotic UTI Treatment HUENA

Cipla launches HUENA, India’s first non-antibiotic drug to treat UTIs

Cipla rolls out nation’s first non-antibiotic medication for recurrent UTI cases

Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva

Buy Cipla; target of Rs 1754: Mirae Asset Sharekhan

Cipla Adjusts Evaluation Amid Mixed Performance Indicators and Growth Prospects

Cipla acquires 20% stake in iCaltech Innovations

Cipla recalls over 20000 packs of inhalation drug in US

Key triggers for these three pharma stocks - Dr Reddy’s Lab, Cipla, Biocon

Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US

Cipla completes 20% stake acquisition in Bengaluru’s iCaltech Innovations

Cipla Recalls Inhalation Drug in US

Cipla recalls inhalation drug in US over quality concerns

Viatris Locks Cipla Out Of Generic Yupelri Market Until 2039

Compliance Lead (Legal) Vacancy At Cipla India [Apply Now]

Cipla completes acquisition of 20% voting rights in Icaltech

Stock Picks Today: ITC Hotels, Bajaj Finance, Cipla, Trent, Lemon Tree On Brokerages Radar

Cipla in talks with Eli Lilly for diabetes drug, say sources; shares in green

Stocks to buy: Rajesh Palviya of Axis Sec suggests Cipla, Lemon Tree Hotels, Cummins India shares in the near-term

Cipla's Stock Performance Signals Potential Trend Reversal Amid Market Outperformance

Five Stocks To Buy Today: Devyani, Cipla, IndusInd Bank And Others—Check Target Price

Dr. Reddy’s, Cipla Lead Nifty Gains; IndusInd, Bajaj-Auto Fall

Cipla shares rise 2.73% on Nifty 50

Cipla Breakout Signals Room For Rally: SEBI Analyst Sees 10% Upside Potential In Near Term

Nifty Top Gainers Today: Dr Reddys Labs, Cipla, L&T stocks lead on Nifty 50 index

NSE NIFTY & CIPLA – Trading Updates

Cipla Shows Mixed Technical Trends Amid Strong Financial Health and Market Positioning

Theravance Biopharma Settles Patent Dispute with Cipla

CIPLA Stock Price and Chart — NSE:CIPLA

Cipla Limited's (NSE:CIPLA) one-year returns climbed after last week's 5.3% gain, institutional investors must be happy

Cipla shares jump 2.6% on Wednesday, among top gainers on Nifty 50

Cipla Ltd spurts 2.93%, gains for third straight session

SES ESG Research Pvt Ltd assigns ESG rating of 69.3 to Cipla Ltd

Growth prescription: The future is specialty; Sun Pharma, Dr Reddy’s, Cipla lead, says Nomura

Cipla Ltd. - Positive Breakout: These 10 stocks close cross above their 200 DMA

Cipla: India business reset and emerging market challenges crimp earnings expectations